28/04/2026
2viewsAPASL 2026 Istanbul: Key Clinical Takeaways Every Hepatologist Needs to Know
APASL 2026 in Istanbul covered 60+ topics across liver disease. Here are the most clinically impactful updates your practice needs.
Quick Answer
APASL 2026 in Istanbul covered 60+ topics across liver disease. Here are the most clinically impactful updates your practice needs.
.png)
You walked out of Istanbul having sat through four days of world-class hepatology - or you didn't attend and you're now trying to piece together what shifted. Either way, APASL 2026 was not a conference of small refinements. Across 60-plus topics, several fault lines in clinical hepatology were exposed, debated, and - in some cases - resolved. This post gives you the high-yield clinical signal without the noise.
The 35th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2026) ran April 22–25, 2026 at the Istanbul Lütfi Kırdar International Convention and Exhibition Centre. The scientific program was dense - spanning viral hepatitis, metabolic liver disease, liver transplantation, portal hypertension, endohepatology, and the rapidly expanding territory of AI in hepatology. The challenge after any major conference is not finding information - it's filtering it. What follows are the APASL 2026 hepatology conference highlights that carry the most direct relevance to clinical decision-making.
MAFLD Redefines Its Metabolic Footprint - And Its Surgical Destiny
MAFLD dominated the conference across multiple sessions, and the message was not simple. Topics ranged from pathophysiology to metabolic complications to liver transplantation outcomes in the MAFLD era. The current understanding, reinforced at APASL 2026, is that MAFLD is not a hepatic disease with metabolic overlap - it is a systemic metabolic disease that happens to cause liver injury. This distinction matters clinically because it changes how you frame risk, how you counsel patients, and increasingly, who you refer for transplant evaluation.
The session "Liver Transplantation in the Era of MAFLD: Challenges and Future Perspectives" addressed what is becoming a structural problem: MAFLD is now one of the fastest-growing transplant indications globally, yet these patients arrive with a metabolic comorbidity burden - diabetes, obesity, cardiovascular disease - that significantly complicates both listing and post-transplant outcomes. The 2024 EASL Clinical Practice Guidelines on MAFLD, referenced in several talks, acknowledge that standard listing criteria were not built for this patient population. The conference sessions did not resolve this tension but made one thing clear: the transplant hepatologist managing MAFLD in 2026 is navigating a framework that is actively being rebuilt beneath them.
On the fibrosis side, two sessions on hepatic stellate cell biology - including new data on the THBS2–SPP1 axis and microfibril-associated glycoprotein 4 - brought the molecular mechanisms of fibrogenesis and regression into sharp focus. GSTM3 plasma levels were presented as a clinically validated non-invasive fibrosis biomarker, and the CT-based quantitative evaluation of hepatic steatosis session reinforced the shift toward objective, reproducible imaging-based assessment tools over clinician estimation. The AI-Based Fibrosis Stage Estimator featured at the conference aligns directly with this trajectory - moving fibrosis assessment out of the biopsy room and into the radiology report and clinic workflow.
Clinical scenario: MAFLD, Metabolic Syndrome, and the Transplant Decision
A 58-year-old woman with type 2 diabetes, BMI 34, and biopsy-confirmed MASH cirrhosis (F4) presents with her first episode of hepatic decompensation - ascites requiring paracentesis, MELD-Na 16. She has no alcohol history, no viral serology, and was never considered a transplant candidate because of her weight.
The APASL 2026 framing challenges the reflexive hesitation here. Obesity alone is no longer a transplant exclusion at most experienced centers. What matters is functional status, cardiovascular risk stratification, bariatric surgery eligibility, and the likelihood of post-transplant metabolic control. Per the discussion in the transplantation sessions, centers with formal MAFLD transplant protocols - incorporating cardiology co-management and pre-transplant weight optimization - are reporting outcomes comparable to non-MAFLD etiologies. Waiting until she decompensates further while applying outdated exclusion criteria is a missed window.
Hepatitis B in 2026: The Goal Has Changed - Functional Cure Is Now the Target
Two dedicated HBV sessions at APASL 2026 - "New Biomarkers for Hepatitis B Infection" and "Future Research Areas in Hepatitis B" - were built around a single premise: suppressing the virus is no longer enough. The field has shifted definitively toward functional cure, defined as sustained HBsAg loss with or without seroconversion, off therapy.
The biomarker landscape has expanded significantly. HBsAg quantification, HBcrAg (hepatitis B core-related antigen), and pgRNA (pregenomic RNA) are now used in combination at specialist centers to predict functional cure probability, guide when to stop NUC therapy, and identify patients who may respond to finite treatment regimens. Per data presented at APASL and consistent with the 2024 APASL HBV Management Guidelines, patients with low HBsAg (<100 IU/mL) at the end of NUC treatment and undetectable pgRNA have significantly higher rates of sustained HBsAg loss post-treatment cessation. This is not a marginal finding - it represents a treatment endpoint redefinition.
The sessions on immune modulators in HBV treatment and entry inhibitors + siRNA/antisense therapies mapped the pipeline clearly: capsid assembly modulators, RNAi agents, and checkpoint inhibitor combinations are all in advanced trials. The immune tolerance state that makes HBV so difficult to clear is the explicit target. Clinicians managing chronic HBV patients in 2026 should be documenting HBsAg quantification at every annual assessment - not just viral load - to position patients appropriately for emerging finite treatment protocols.
A frequently overlooked point: Acute Liver Failure Timing Is Not Intuitive
The APASL 2026 session on "Acute Liver Failure and Liver Transplantation: Timing and Benefit" underscored a point that experienced hepatologists know but that gets lost in clinical urgency: the window for transplantation in ALF is both narrow and difficult to identify in real time. The APASL ALF criteria (INR ≥1.5 plus hepatic encephalopathy in the absence of pre-existing liver disease) define the syndrome, but they do not tell you when a patient has crossed the threshold from potentially recoverable to definitively needing a graft. Clinicians frequently wait too long - applying Kings College Criteria or MELD cutoffs after the opportunity has already narrowed. The session reinforced that early hepatology/transplant co-management in any suspected ALF case, before criteria are formally met, is associated with better outcomes. Do not wait for encephalopathy to grade 3–4 before calling transplant surgery.
Bottom line for clinical practice
MAFLD patients with cirrhosis should not be reflexively excluded from transplant listing on the basis of BMI alone - formal pre-transplant metabolic evaluation with cardiology co-management is now the standard at expert centers.
HBsAg quantification and pgRNA should be measured annually in all chronic HBV patients on NUC therapy - these markers now predict functional cure probability and guide stop decisions.
Non-invasive fibrosis tools (CT-based steatosis quantification, plasma GSTM3, AI-based staging) are moving from research settings to clinical integration - familiarise yourself with their local availability now.
In acute liver failure, transplant co-management should begin at suspicion, not at confirmed criteria - the window is narrow and deterioration is non-linear.
The endohepatology sessions confirmed EUS-guided therapies are no longer niche - EUS-guided liver biopsy, portal pressure measurement, and therapeutic interventions are becoming standard tools in centres with interventional hepatology expertise.
APASL 2026 covered a lot of ground. The cases you face tomorrow will be shaped by decisions taken in Istanbul this week - whether you were in the room or not. When a chronic HBV patient asks about stopping treatment, or a MAFLD patient with early cirrhosis asks what comes next, GastroAGI can walk through the clinical details with you in real time, applying current guideline logic to the specific patient in front of you.
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.